| Abstract | Following the demonstration of the superior validity of human papillomavirus (HPV) tests in screening for cervical cancer and the arrival of highly efficacious HPV 16 and 18 vaccines, cervical cancer prevention enters a time of sustainable introduction in developing countries. Multidisciplinary efforts and novel protocols are being developed, and challenging situations are being faced to make cervical cancer, still the number two cancer in women worldwide, an eradicable condition. |
| Authors | F X Bosch, X Castellsagué, S de Sanjosé
(Affiliation: Cancer Epidemiology and Registration Unit, IDIBELL, Institut Català d'Oncologia, L'Hospitalet del Llobregat, Barcelona, Spain. x.bosch at iconcologia.net)
|
| Journal | British journal of cancer
(Br J Cancer)
Vol. 98
Issue 1
Pg. 15-21
(Jan 15 2008)
ISSN: 0007-0920 England |
| PMID | 18182975
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
| Chemical References |
|
| Topics |
- Female
- Human papillomavirus 16
(immunology)
- Human papillomavirus 18
(immunology)
- Humans
- Immunotherapy
- Papillomavirus Infections
(prevention & control, virology)
- Papillomavirus Vaccines
(administration & dosage)
- Uterine Cervical Neoplasms
(prevention & control, virology)
- Vaccination
|
